Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST) From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death [clinicaltrials_resource:5e23046e2d17aeded1a220ff591d6699]
TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death. Diagnosis of progressive disease was done according to RECIST (Version 1.0) and/or investigator assessment based on RECIST. RECIST criteria used changes in the largest diameter of target/non-target lesions. Target (measurable) lesions were up to a maximum of 5 per organ & >20 mm by clinical imaging (>=10 mm with spiral CT scan). Non-target lesions were all other lesions.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST) From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death [clinicaltrials_resource:5e23046e2d17aeded1a220ff591d6699]
TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death. Diagnosis of progressive disease was done according to RECIST (Version 1.0) and/or investigator assessment based on RECIST. RECIST criteria used changes in the largest diameter of target/non-target lesions. Target (measurable) lesions were up to a maximum of 5 per organ & >20 mm by clinical imaging (>=10 mm with spiral CT scan). Non-target lesions were all other lesions.
Bio2RDF identifier
5e23046e2d17aeded1a220ff591d6699
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:5e23046e2d17aeded1a220ff591d6699
measure [clinicaltrials_vocabulary:measure]
Time to Disease Progression (T ...... teria in Solid Tumors (RECIST)
time frame [clinicaltrials_vocabulary:time-frame]
From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death
description
TTP was defined as the time fr ...... esions were all other lesions.
identifier
clinicaltrials_resource:5e23046e2d17aeded1a220ff591d6699
title
Time to Disease Progression (T ...... f Progressive Disease or Death
@en
type
label
Time to Disease Progression (T ...... 3046e2d17aeded1a220ff591d6699]
@en